International Urology and Nephrology

, Volume 45, Issue 3, pp 795–802

Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature

  • Wai Yew Kong
  • Ramyasuda Swaminathan
  • Ashley Irish
Nephrology - Original Paper



B cell-targeted immunosuppression with rituximab as primary treatment or when conventional therapy is contraindicated or unsuccessful can induce remission in idiopathic membranous nephropathy (IMN). We explored the efficacy and safety of rituximab therapy in an adult population with IMN and other primary glomerulonephritides.


This study is a single-centre retrospective case review of 24 adult patients who received rituximab (RTX) for IMN (n = 11), minimal change disease (MCD, n = 7), focal segmental glomerulosclerosis (FSGS, n = 4), and membranoproliferative glomerulonephritis (MPGN, n = 2). Outcomes included the proportion of patients with complete and partial remission, frequency of relapse, the amount of post-RTX immunosuppression, and toxicity.


The median follow-up for all patients was 31.5 months (IQR: 15.0–44.0). Rituximab therapy induced remission in 19/24 (79.2 %) patients (IMN: 63.6 %, MCD: 100 %, FSGS: 75 %, and MPGN: 100 %). Disease recurrence in patients with ≥3 relapses pre-RTX therapy (MCD, n = 6 and FSGS, n = 1) decreased from 37.0 to 19.6 events per 1,000 patient-months. All patients with steroid maintenance, discontinued or achieved at least a 50 % dose reduction at 3.0 months (IQR: 1.5–8.0) post-treatment. One patient ceased CSA in addition to a 50 % steroid dose reduction 13 months post-RTX. Rituximab was well tolerated with a single serious infection (4.2 %) responsive to treatment.


Rituximab induced remission in IMN comparable with published reports but had an additional benefit in inducing remission in other common glomerulonephritides. Additional randomized studies are needed to confirm its potential therapeutic benefit and optimal dosing for adult-onset primary glomerulonephritis.


B lymphocyte Primary glomerulonephritis Rituximab 


  1. 1.
    Ahmed MS, Wong CF (2008) Rituximab and nephrotic syndrome: a new therapeutic hope? Nephrol Dial Transplant 23:11–17PubMedCrossRefGoogle Scholar
  2. 2.
    Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G (2007) Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2:932–937PubMedCrossRefGoogle Scholar
  3. 3.
    Fervenza FC, Abraham RS, Erickson SB et al (2010) Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol 5:2188–2198PubMedCrossRefGoogle Scholar
  4. 4.
    Ruggenenti P, Chiurchiu C, Abbate M et al (2006) Rituximab for idiopathic membranous nephropathy: who can benefit? Clin J Am Soc Nephrol 1:738–748PubMedCrossRefGoogle Scholar
  5. 5.
    Johnson PWM, Glennie MJ (2001) Rituximab: mechanisms and applications. Br J Cancer 85:1619–1623PubMedCrossRefGoogle Scholar
  6. 6.
    Mathieson P (2007) Minimal change nephropathy and focal segmental glomerulosclerosis. Semin Immunopathol 29:415–426PubMedCrossRefGoogle Scholar
  7. 7.
    Shalhoub RJ (1974) Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet 2:556–560PubMedCrossRefGoogle Scholar
  8. 8.
    Wei C, Reiser J (2011) Minimal change disease as a modifiable podocyte paracrine disorder. Nephrol Dial Transplant 26:1776–1777PubMedCrossRefGoogle Scholar
  9. 9.
    Kemper MJ, Meyer-Jark T, Lilova M, Müller-Wiefel DE (2003) Combined T- and B-cell activation in childhood steroid-sensitive nephrotic syndrome. Clin Nephrol 60:242–247PubMedGoogle Scholar
  10. 10.
    Hristea D, Hadaya K, Marangon N et al (2007) Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int 20:102–105PubMedCrossRefGoogle Scholar
  11. 11.
    Pescovitz MD, Book BK, Sidner RA (2006) Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 354:1961–1963PubMedCrossRefGoogle Scholar
  12. 12.
    Bagga A, Sinha A, Moudgil A (2007) Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med 356:2751–2752PubMedCrossRefGoogle Scholar
  13. 13.
    Guigonis V, Dallocchio A, Baudouin V et al (2008) Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 23:1269–1279PubMedCrossRefGoogle Scholar
  14. 14.
    Gulati A, Sinha A, Jordan SC et al (2010) Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol 5:2207–2212PubMedCrossRefGoogle Scholar
  15. 15.
    Fernandez-Fresnedo G, Segarra A, González E et al (2009) Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 4:1317–1323PubMedCrossRefGoogle Scholar
  16. 16.
    Hoxha E, Stahl RAK, Harendza S (2011) Rituximab in adult patients with immunosuppressive-dependent minimal change disease. Clin Nephrol 76:151–158PubMedGoogle Scholar
  17. 17.
    Fujinaga S, Hirano D, Nishizaki N et al (2010) Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol 25:539–544PubMedCrossRefGoogle Scholar
  18. 18.
    Bartel C, Obermã Ller N, Rummel MJ, Geiger H, Hauser IA (2008) Remission of a B cell CLL-associated membranoproliferative glomerulonephritis type I with rituximab and bendamustine. Clin Nephrol 69:285–289PubMedGoogle Scholar
  19. 19.
    Bestard O, Cruzado JM, Ercilla G et al (2006) Rituximab induces regression of hepatitis C virus-related membranoproliferative glomerulonephritis in a renal allograft. Nephrol Dial Transplant 21:2320–2324PubMedCrossRefGoogle Scholar
  20. 20.
    Kamei K, Ito S, Nozu K et al (2009) Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 24:1321–1328PubMedCrossRefGoogle Scholar
  21. 21.
    Kimby E (2005) Tolerability and safety of rituximab (MabThera®). Cancer Treat Rev 31:456–473PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, B.V. 2012

Authors and Affiliations

  • Wai Yew Kong
    • 1
    • 3
  • Ramyasuda Swaminathan
    • 1
    • 2
  • Ashley Irish
    • 1
  1. 1.Department of Nephrology and TransplantationRoyal Perth HospitalPerthAustralia
  2. 2.School of Medicine and PharmacologyUniversity of Western AustraliaPerthAustralia
  3. 3.Division of Nephrology, Department of MedicineUniversity Malaya Medical CentreKuala LumpurMalaysia

Personalised recommendations